Arcus (RCUS) Q2 2026 earnings review
Pivoting Hard: Casdatifan Takes Center Stage as TIGIT Ends
Arcus is completing a brutal but necessary strategic pivot. With Q2 revenue coming in at $41M (bolstered by Gilead option expirations and Taiho milestones), the spotlight is squarely on cost control and pipeline consolidation. Net loss narrowed to $91M as R&D expenses decelerated to $113M. This reflects the final death knell of the domvanalimab (anti-TIGIT) program, punctuated by the termination of the PACIFIC-8 study and Gilead's departure from the Arcus board. Management is now betting its $775M cash pile almost entirely on casdatifan, striking three new clinical collaborations to test the HIF-2α inhibitor with novel bispecifics. The runway to H2 2028 looks secure, but Arcus is now a high-stakes, single-asset execution story.
🐂 Bull Case
Aggressive R&D cost-cutting ($113M, down 19% YoY) and new cost-sharing collaborations solidify the cash runway into late 2028, giving the company time to execute the Phase 3 PEAK-1 trial.
The new collaborations with BMS, Summit, and AVEO allow Arcus to evaluate casdatifan across multiple combinations without shouldering the massive financial burden of full trial sponsorship.
🐻 Bear Case
Gilead's exit from the board and the final termination of the TIGIT program confirms a massive pipeline failure, transforming Arcus into a binary bet on casdatifan's success.
The $41M Q2 revenue beat was largely driven by Gilead option expirations. As legacy collaborations wind down, top-line revenue will shrink dramatically.
⚖️ Verdict: ⚪
Neutral. The financial discipline is commendable and the cash position is a fortress, but the margin for clinical error is now zero. Arcus is a pure-play bet on a single molecule outperforming Merck's established incumbent.
Key Themes
Rapid Casdatifan Partnership Expansion
Instead of shouldering the massive costs of combination trials alone, Arcus secured three new clinical collaborations with BMS (pumitamig), Summit (ivonescimab), and AVEO (tivozanib). This strategy efficiently evaluates casdatifan alongside cutting-edge bispecifics and TKIs in 1L and late-line ccRCC. It accelerates the goal of making casdatifan a foundational backbone without breaking the R&D budget.
The TIGIT Overhang Ends in Surrender
The anti-TIGIT dream is over. Following prior study discontinuations, Arcus and AstraZeneca have axed the Phase 3 PACIFIC-8 study for domvanalimab. Consequently, Gilead has relinquished all three of its board seats. Despite management pointing to the positives of cash preservation, this officially zeroes out a program that previously drove a massive $143M license catch-up payment just a year ago (25Q2), leaving a gaping hole in the pipeline's perceived value.
Decelerating R&D Spend Secures Runway
Management is forcefully reining in expenses. R&D dropped from $139M in 25Q2 to $113M this quarter. With the TIGIT trials winding down and the company avoiding full sponsorship of its new bispecific combination trials, Arcus projects continued near-term expense deceleration. This cost rationalization is the only way the company can hit its projection of $600M in year-end cash.
Quietly Building an Immunology Hedge
Arcus is utilizing its small-molecule discovery engine to build a lifeboat outside of oncology. The lead I&I asset, AB102 (an oral MRGPRX2 antagonist), enters Phase 1 human trials this month. An oral TNF inhibitor is slated for early 2027. While extremely early, these programs target massive, validated commercial markets and provide essential strategic optionality.
Binary Execution Risk on ARC-20
Despite the new combinations, Arcus is now a 'show-me' story centered exclusively on casdatifan. The company needs to prove not only that its drug is superior to Merck's belzutifan, but that its ambitious multi-trial ARC-20 plan can be executed on time. Any safety signals from the new bispecific combinations or delays in the PEAK-1 Phase 3 enrollment (targeted for year-end 2026) would decimate the remaining valuation.
Other KPIs
Decreased from $876M in 26Q1 and $1.01B at year-end 2025, reflecting ~$101M in quarterly burn. However, management projects ending 2026 at ~$600M, implying an acceleration of cost savings to stretch the runway into the second half of 2028.
Down from $29M in the prior year period, reflecting early signs of streamlining initiatives across operations in tandem with the R&D clinical cuts.
Guidance
Accelerating versus previous internal projections (prior guide was $50-$65M). The bump is largely administrative, reflecting access rights revenue recognized in June upon the expiration of Gilead's options, plus a $15M Taiho milestone.
Decelerating cash burn. Implies ~$175M of total burn in the second half of 2026 (down from ~$235M burned in the first half). Hitting this target is essential for maintaining the stated H2 2028 runway without toxic dilution.
Key Questions
Gilead Operational Dynamics
With Gilead stepping off the board and the TIGIT program terminated, how does this structurally alter the operational dynamics and funding mechanisms of the broader collaboration moving forward?
Bispecific Prioritization
You have announced multiple new casdatifan combinations with novel bispecifics. How will you prioritize these cohorts if multiple signals look promising, given your stated budget constraints?
Front-line Go/No-Go Metrics
What specific data points from the ARC-20 first-line cohorts (expected in H2 2026) will constitute the 'go/no-go' decision threshold for initiating the planned PEAK-20 Phase 3 trial?